Cerebrolysin is a porcine brain-derived peptide preparation containing a standardized mixture of low-molecular-weight neuropeptides and free amino acids. It has been used clinically in Europe, Asia, and Russia for decades across indications including stroke recovery, traumatic brain injury (TBI), and dementia. This protocol covers the practical framework for neuroprotection and cognitive enhancement applications.

What cerebrolysin is — and is not

Cerebrolysin is not a single peptide. It is a complex biological mixture produced by enzymatic hydrolysis of purified porcine brain proteins, yielding fragments that include neurotrophic factor-like peptides. Its proposed mechanism involves mimicking the activity of endogenous neurotrophic factors — BDNF, GDNF, NGF, and CNTF — without containing those molecules directly. The active fraction consists of peptides under 10 kDa that cross the blood-brain barrier. It is manufactured by EVER Neuro Pharma (Austria) under pharmaceutical GMP conditions.

Dose selection

Standard neuroprotective dose: 5 mL daily

Higher-dose clinical protocol: 10 mL daily (used in stroke and TBI research)

Neurodegeneration research doses: 10–30 mL daily, typically IV (clinical settings only)

For cognitive enhancement and neuroprotection outside acute neurological emergencies, 5 mL IM daily is the standard starting point. The 10 mL dose is reasonable for individuals with specific neurological concerns (post-concussion recovery, early cognitive decline) but should not be the default first-cycle dose.

Doses above 10 mL are administered intravenously in clinical settings, diluted in 100–250 mL normal saline over 15–60 minutes. These doses are outside the scope of self-administered protocols and should only be used under medical supervision.

Route of administration

Primary route: Intramuscular (IM) injection

Site: Gluteal muscle (upper outer quadrant) or deltoid for smaller volumes

Volume limit per IM site: 5 mL. For 10 mL doses, split between two injection sites.

IV administration is standard in clinical neurology settings (stroke units, rehabilitation hospitals) where higher doses are used. IM is the practical route for outpatient neuroprotective protocols. Subcutaneous injection is not recommended — the volume and formulation characteristics are designed for IM or IV delivery.

Cycle structure

Standard course: 10–20 consecutive daily injections

Optimal course length: 20 days (this is the duration used in most clinical trials)

Courses per year: 2–3, spaced at least 8–12 weeks apart

Rest period between courses: Minimum 2 months

The cycling approach reflects how cerebrolysin has been used in European and Russian clinical practice for decades. The rationale is that neurotrophic stimulation produces effects that outlast the treatment period — neuroplastic changes, synaptic remodeling, and dendritic growth continue after the peptide is cleared. Continuous indefinite use has not been studied and is not recommended.

Typical annual schedule:

Course 1: 20 days on
2–3 months off
Course 2: 20 days on
2–3 months off
Course 3 (optional): 20 days on

Combination with semax and selank

Cerebrolysin is frequently stacked with other nootropic peptides, most commonly semax and selank, for a multi-mechanism cognitive protocol.

Cerebrolysin + Semax stack:

Cerebrolysin: 5 mL IM daily (during the 20-day course)
Semax: 200–600 mcg intranasal, morning dosing (can continue between cerebrolysin courses)
Rationale: Cerebrolysin provides broad neurotrophic support while semax adds dopaminergic activation and additional BDNF upregulation through a different delivery route and receptor profile

Cerebrolysin + Selank (or NA-Selank Amidate) stack:

Cerebrolysin: 5 mL IM daily
Selank: 200–400 mcg intranasal, 1–2 times daily
Rationale: Selank's GABAergic and anxiolytic effects complement cerebrolysin's neurotrophic action — particularly relevant for individuals whose cognitive decline has an anxiety or stress component

Triple stack (cerebrolysin + semax + selank):

Used by some practitioners for comprehensive cognitive support
Cerebrolysin provides the neurotrophic base; semax adds activation and focus; selank adds anxiolysis and emotional stabilization
Administer semax in the morning, selank in the afternoon or as needed, cerebrolysin IM at a consistent daily time

Monitoring approach

Before starting (baseline):

Cognitive assessment: standardized test battery (MoCA, or app-based tools like Cambridge Brain Sciences) to establish baseline scores
Subjective journal: daily ratings of mental clarity, memory recall, verbal fluency, and fatigue
If available: quantitative EEG (qEEG) for objective neurophysiological baseline

During the course:

Track subjective cognitive measures daily
Note any injection site reactions (soreness, bruising — typically mild and transient)
Watch for headache in the first 3–5 days (common, usually resolves; reduce dose to 2.5 mL temporarily if persistent)

Post-course assessment (1–2 weeks after completing the course):

Repeat cognitive testing to compare against baseline
Evaluate whether improvements justify additional courses
Benefits are typically reported as cumulative across multiple courses — a single 10-day course may produce modest results, with more noticeable changes after 2–3 courses

Evidence reality check

Cerebrolysin occupies a complicated position in evidence-based medicine. There is more clinical data than for most nootropic peptides, but the quality is uneven.

What the data supports:

Phase III trials in Alzheimer's disease (CERE-101, CERE-201) showed improvements in cognitive scales (ADAS-cog) and global clinical impression over 24 weeks. Effect sizes were modest but statistically significant.
TBI studies demonstrated improved cognitive recovery and functional outcomes when cerebrolysin was administered within the acute phase.
Stroke recovery trials (particularly in Asia and Europe) showed benefits in neurological rehabilitation scores.

What the data does not support:

Cerebrolysin as a replacement for established dementia therapies (cholinesterase inhibitors, memantine)
Use as a cognitive enhancer in healthy young adults — clinical trials have focused on impaired populations
Any claim of neuroregeneration in established, late-stage neurodegeneration

Key limitations:

Most trials were conducted in Eastern Europe and Asia; representation in major Western guideline bodies is limited
The Cochrane review on cerebrolysin for dementia concluded "possible benefit" but called for larger, higher-quality trials
The complex biological nature of the preparation makes mechanistic attribution difficult — it is unclear which specific peptide fractions drive the observed effects

Cerebrolysin is a reasonable neuroprotective intervention backed by more clinical evidence than most peptide protocols, but users should calibrate expectations: it is a modest-effect, evidence-supported adjunct — not a dramatic cognitive transformation.